Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-related Weight Loss
Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
Explore weight gain in HIV-positive patients who have weight loss associated with
AIDS-related wasting (anorexia/cachexia). Patients are treated for 12 weeks with either
megestrol acetate oral suspension nanocrystal dispersion formulation, or megestrol acetate
oral suspension original formulation